Dr. Axel Gille reports

AURORA AND ETHYPHARM REAFFIRM THEIR COMMITMENT TO PROMOTE ACCESS TO MEDICAL CANNABIS FOR FRENCH PATIENTS

Aurora Europe GmbH, a subsidiary of Aurora Cannabis Inc., and Ethypharm have once again been selected by the French general directorate of health (DGS) as exclusive suppliers of dried medical cannabis flower until the end of the French trial period. The trial has recently been extended until March, 2024.

"We are delighted to have been selected once again to continue to supply high-quality dried medical cannabis flower to the French pilot program. Driven by our purpose of opening the world to cannabis, Aurora continues to work hand in hand with government officials, physicians and pharmacists to reduce stigma and further develop medical markets throughout Europe," says Dr. Axel Gille, president of Aurora Europe.

Aurora and Ethypharm signed an agreement to serve the French pilot program, led by the National Agency for the Safety of Medicines and Health Products (ANSM), in October, 2020, leveraging both parties' expertise. Under the terms of the exclusive partnership, Aurora supplies medical cannabis, as well as EU GMP (good manufacturing practices) manufacturing and logistics support. Distribution and pharmacovigilance activities continue to be handled by Ethypharm Laboratories, Ethypharm's French sales subsidiary.

Within the framework of the extension of the trial, the DGS opened a call for tenders to supply medical cannabis in January, 2023. In March, Aurora Europe and Ethypharm were selected to continue to provide medical cannabis produced according to European GMP standards to patients included in the study.

As committed partners, Ethypharm and Aurora Europe reaffirm their commitment to patients and health care professionals to improve the status and accessibility of medical cannabis in Europe.

"By planning to make Aurora's pharmaceutical-grade medical cannabis available in France, we wish to reinforce our expertise in central nervous system pathologies, and in particular in pain treatment. We are proud to move forward with the French health authorities and health professionals in this experimentation which, we hope, will show the interest of the use of medical cannabis to relieve French patients from certain symptoms such as pain," says Frederic Arnal, general manager of Ethypharm Laboratories.

We seek Safe Harbor.